MARKET

PCRX

PCRX

Pacira Biosciences Inc
NASDAQ
23.98
-0.21
-0.87%
After Hours: 23.98 0 0.00% 16:01 12/04 EST
OPEN
24.13
PREV CLOSE
24.19
HIGH
24.34
LOW
23.90
VOLUME
573.73K
TURNOVER
--
52 WEEK HIGH
27.64
52 WEEK LOW
16.41
MARKET CAP
1.03B
P/E (TTM)
51.42
1D
5D
1M
3M
1Y
5Y
1D
PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain
NASDAQ · 1d ago
Pacira Biosciences Grants Inducement Awards to New Employees
Reuters · 1d ago
PACIRA BIOSCIENCES REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 1d ago
Pacira announces results from 12-month pilot study on iovera
TipRanks · 2d ago
PACIRA BIOSCIENCES ANNOUNCES RESULTS FROM 12-MONTH PILOT STUDY DEMONSTRATING FAVORABLE SAFETY AND SIGNIFICANT IMPROVEMENTS IN PAIN WITH IOVERA° COMPARED TO RADIOFREQUENCY ABLATION IN CHRONIC LOW BACK PAIN
Reuters · 2d ago
Pacira BioSciences Announces Results From Randomized 30-Patient Pilot Study Evaluating Iovera° Cryoneurolysis Versus Radiofrequency Ablation For Chronic Low Back Pain
Benzinga · 2d ago
Pacira Biosciences Study Finds Iovera° Superior to Radiofrequency Ablation for Chronic Low Back Pain
Reuters · 2d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (PCRX), Pfizer (PFE) and Janux Therapeutics Inc (JANX)
TipRanks · 2d ago
More
About PCRX
Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.

Webull offers Pacira Biosciences Inc stock information, including NASDAQ: PCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCRX stock methods without spending real money on the virtual paper trading platform.